Large Cell Lung Carcinoma Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Carcinoma, Large Cell Lung

IndicationStatusPhase
DBCOND0044133 (Large Cell Lung Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01294306MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyTreatment